



14 November 2008

PRESS RELEASE

IMPEDIMED CHOSEN FOR AUSTRALIAN INNOVATION SHOOT OUT IN U.S.

ImpediMed CEO, Greg Brown today announced that ImpediMed will represent Queensland in the Australian Innovation Shoot Out at next year's G'Day USA: Australia Week.

The Shoot Out, to be held on 15 January 2009, will showcase Queensland's strengths in the Biotechnology and Therapeutic Medicines and Devices sector.

Mr Brown said the Shoot Out will see ImpediMed capitalise upon its strong U.S. presence.

"With first-to-market advantage for the FDA-cleared L-Dex™ U400 device and U.S. operations headquarters in San Diego, ImpediMed will promote Queensland's ability to provide innovative solutions to aid medical professionals in the clinical assessment of a common morbidity issue related to cancer treatment - Lymphoedema," he said.

"This unique profiling opportunity complements ImpediMed's overall U.S. marketing campaign, helping the company to strategically position itself within the U.S. market. We are extremely thankful to the Queensland Government for all their continuing support and we are particularly grateful for this opportunity.

"Through the event, ImpediMed will have the opportunity to engage with key business decision makers and look for real trade and investment outcomes.

ImpediMed will first present in Los Angeles and then compete in the Shoot Out in Silicon Valley, in front of a panel of high profile American judges. ImpediMed will also have the opportunity for one-on-one meetings and networking between investors and finalists.

With more than 15,000 participants in 2008, Australia Week is now the largest annual foreign country promotion in the U.S.

ENDS

For further information contact:

Greg Brown
Stephanie Paul

Impedimed CEO
Phillips Group

+61-7-3860-3700
+61-7-3230-5000 or +61-418-753-062

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.